Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
130 Pages - GMD12052
$2,000.00

Summary

Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Refractory Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Refractory Chronic Lymphocytic Leukemia (CLL) Overview 8
Therapeutics Development 9
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview 9
Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17
Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 18
Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
AstraZeneca PLC 20
GlaxoSmithKline plc 21
MedImmune, LLC 22
Infinity Pharmaceuticals, Inc. 23
Novartis AG 24
Astex Pharmaceuticals, Inc. 25
Celgene Corporation 26
Portola Pharmaceuticals, Inc. 27
Pharmacyclics, Inc. 28
MorphoSys AG 29
Threshold Pharmaceuticals, Inc. 30
SBI Biotech Co., Ltd. 31
AbbVie Inc. 32
SpectraMab GmbH 33
Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 39
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ibrutinib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
duvelisib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
venetoclax - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
venetoclax + rituximab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AT-7519 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MOR-208 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MEDI-551 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CTL-019 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
afuresertib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PRT-2070 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Gene Modified T Cells for Leukemia - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
TH-302 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
GNKG-168 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
CC-292 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
BMS-986016 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
AZD-6738 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
venetoclax + obinutuzumab - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Triplebody 19x16x19 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Refractory Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 85
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 118
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 119
Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 120
Featured News & Press Releases 120
Dec 03, 2013: MorphoSys Strengthens European Patent Position on anti-CD19 Cancer Program MOR208 120
Nov 25, 2013: TG Therapeutics Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL 120
Oct 22, 2013: MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208 121
Oct 07, 2013: MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208 121
Jun 19, 2013: Janssen Announces Publication Of Phase Ib/II Trial Data Of Ibrutinib In Relapsed Or Refractory Chronic Lymphocytic Leukemia In The New England Journal Of Medicine 122
Jun 17, 2013: AbbVie Presents Preliminary Results From Phase I Study Of ABT-199/GDC-0199 In Patients With High-Risk CLL At EHA Annual Meeting 123
May 15, 2013: Onyx Pharma To Present Data On Kyprolis At 49th American Society Of Clinical Oncology Annual Meeting 125
Mar 25, 2013: Genmab And GSK Announce Japanese Approval Of Leukemia Drug Arzerra 126
Aug 01, 2012: Pharmacyclics To Receive $50m Milestone Payment From Janssen Biotech 126
Jun 16, 2012: Pharmacyclics Announces Updated Results For Ibrutinib Combination Study At European Hematology Association Annual Congress 127
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Tables
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2014 19
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca PLC, H1 2014 20
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by GlaxoSmithKline plc, H1 2014 21
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H1 2014 22
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 23
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2014 24
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 25
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2014 26
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 27
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2014 28
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2014 29
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 30
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by SBI Biotech Co., Ltd., H1 2014 31
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2014 32
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by SpectraMab GmbH, H1 2014 33
Assessment by Monotherapy Products, H1 2014 34
Assessment by Combination Products, H1 2014 35
Number of Products by Stage and Target, H1 2014 38
Number of Products by Stage and Mechanism of Action, H1 2014 41
Number of Products by Stage and Route of Administration, H1 2014 43
Number of Products by Stage and Molecule Type, H1 2014 45
Refractory Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2014 85
Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2014 118
Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2014 119

List of Figures
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H1 2014 9
Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Assessment by Monotherapy Products, H1 2014 34
Assessment by Combination Products, H1 2014 35
Number of Products by Top 10 Target, H1 2014 36
Number of Products by Stage and Top 10 Target, H1 2014 37
Number of Products by Top 10 Mechanism of Action, H1 2014 39
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 40
Number of Products by Top 10 Route of Administration, H1 2014 42
Number of Products by Stage and Top 10 Route of Administration, H1 2014 43
Number of Products by Top 10 Molecule Type, H1 2014 44
Number of Products by Stage and Top 10 Molecule Type, H1 2014 45

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax